Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Posgrado en Microbiología, Centro de Investigaciones en Ciencias Microbiológicas, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, Puebla, Puebla, 72592, Mexico.
Anaerobe. 2022 Dec;78:102638. doi: 10.1016/j.anaerobe.2022.102638. Epub 2022 Sep 20.
Clostridioides difficile infection (CDI) is a significant worry within healthcare institutions and the community. It is one of the leading agents causing severe diarrhea worldwide. Effective management is critical since the morbidity and mortality attributed to CDI have increased exponentially over the past 20 years. Currently, antibiotics are the standard treatment for primary C. difficile infection, but at the same time, they are associated with disease relapse and increased drug resistance. CDI's high recurrence rates, spore generation, and antimicrobial resistance are currently significant challenges that urge the development of new options to combat this infection. This review describes up-and-coming alternatives and how they can mitigate the challenges associated with CDI. Here we have discussed the advantages and challenges of current and experimental alternatives against CDI.
艰难梭菌感染（CDI）是医疗机构和社区的重大担忧。它是全球范围内导致严重腹泻的主要病原体之一。由于过去 20 年来与 CDI 相关的发病率和死亡率呈指数级增长，因此有效的管理至关重要。目前，抗生素是治疗原发性艰难梭菌感染的标准治疗方法，但同时，它们也与疾病复发和耐药性增加有关。CDI 的高复发率、孢子生成和抗药性是目前的重大挑战，这促使人们开发新的方法来对抗这种感染。本综述描述了新兴的替代品，以及它们如何减轻与 CDI 相关的挑战。在这里，我们讨论了针对 CDI 的现有和实验性替代品的优缺点。
